MaltSci 麦伴科研

Appearance

Popular Reports / Cancer Research

This report is written by MaltSci based on the latest literature and research findings

What are the latest advances in cancer early detection? ​

Abstract ​

The early detection of cancer is a pivotal aspect of oncology that profoundly influences patient survival rates and treatment efficacy. With cancer accounting for a substantial proportion of global mortality, innovative methodologies for early diagnosis are essential. Recent advancements in technology, particularly the integration of artificial intelligence (AI) into diagnostic imaging, have transformed the landscape of cancer detection, enabling more accurate interpretations of radiological data. Additionally, liquid biopsies, which analyze circulating tumor DNA (ctDNA) and other biomarkers in bodily fluids, provide a non-invasive alternative to traditional tissue biopsies, facilitating early detection and personalized treatment strategies. Genomic and proteomic approaches further enhance the discovery of novel biomarkers, improving diagnostic precision. Multi-omics strategies, integrating genomic, transcriptomic, and proteomic data, offer comprehensive insights into tumor biology, aiding in early detection and tailored therapies. However, the clinical implementation of these advancements faces challenges, including regulatory hurdles, ethical considerations, and the need for cost-effective solutions to ensure accessibility across diverse populations. This report synthesizes recent findings and expert opinions, illuminating the current landscape of cancer early detection and the ongoing challenges that must be addressed to translate these innovations into routine clinical practice.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Technological Advances in Imaging Techniques
    • 2.1 Role of Artificial Intelligence in Radiology
    • 2.2 Innovations in MRI and CT Scanning
  • 3 Liquid Biopsies and Circulating Biomarkers
    • 3.1 Overview of Liquid Biopsy Technologies
    • 3.2 Clinical Applications and Case Studies
  • 4 Genomic and Proteomic Approaches to Biomarker Discovery
    • 4.1 Next-Generation Sequencing in Cancer Detection
    • 4.2 Proteomic Profiling and Its Implications
  • 5 Multi-Omics Strategies for Comprehensive Cancer Detection
    • 5.1 Integration of Genomic, Transcriptomic, and Proteomic Data
    • 5.2 Challenges and Future Directions
  • 6 Challenges in Clinical Implementation
    • 6.1 Regulatory and Ethical Considerations
    • 6.2 Accessibility and Cost-Effectiveness
  • 7 Summary

1 Introduction ​

The early detection of cancer remains a critical challenge in the field of oncology, significantly influencing patient outcomes and survival rates. Cancer, which accounts for nearly one in six deaths globally, presents a complex interplay of biological and environmental factors that complicate its diagnosis and treatment [1]. As the understanding of cancer biology evolves, the importance of identifying malignancies at their earliest stages has become increasingly apparent. Early diagnosis can lead to timely interventions, potentially transforming the prognosis for many patients [2].

Recent advancements in technology and research have catalyzed the development of innovative methodologies for cancer detection. The integration of artificial intelligence (AI) into diagnostic imaging has revolutionized the field, enabling more accurate interpretations of radiological data [1]. Additionally, the advent of liquid biopsies, which allow for the analysis of circulating tumor DNA (ctDNA) and other biomarkers in bodily fluids, offers a non-invasive alternative to traditional tissue biopsies [3]. These developments are complemented by genomic and proteomic approaches that facilitate the discovery of novel biomarkers, enhancing the precision of cancer detection [4].

The significance of these advancements cannot be overstated. Effective early detection strategies are essential not only for improving treatment outcomes but also for reducing the overall burden of cancer on healthcare systems [2]. The potential for personalized medicine, driven by insights gained from biomarker research and multi-omics strategies, further underscores the transformative nature of these technologies [5]. However, the path to clinical implementation is fraught with challenges, including regulatory hurdles, ethical considerations, and the need for cost-effective solutions that ensure accessibility across diverse populations [4].

This report aims to provide a comprehensive overview of the latest advances in cancer early detection, organized into several key sections. First, we will explore technological advances in imaging techniques, highlighting the role of AI in radiology and innovations in MRI and CT scanning [1]. Following this, we will delve into liquid biopsies and circulating biomarkers, providing an overview of the technologies involved and their clinical applications [3]. Next, we will examine genomic and proteomic approaches to biomarker discovery, discussing the implications of next-generation sequencing and proteomic profiling [4].

The report will also address the emerging field of multi-omics strategies, emphasizing the integration of genomic, transcriptomic, and proteomic data and the associated challenges and future directions [5]. Finally, we will discuss the challenges in clinical implementation, including regulatory and ethical considerations, as well as issues of accessibility and cost-effectiveness [4].

In summary, this report synthesizes recent findings and expert opinions to illuminate the current landscape of cancer early detection, offering insights into the innovative technologies that are shaping the future of oncology and the ongoing challenges that must be addressed to translate these advances into routine clinical practice.

2 Technological Advances in Imaging Techniques ​

2.1 Role of Artificial Intelligence in Radiology ​

The knowledge base information is insufficient. Please consider switching to a different knowledge base or supplementing relevant literature.

2.2 Innovations in MRI and CT Scanning ​

Recent advancements in imaging techniques have significantly improved the early detection of cancer, particularly through innovations in magnetic resonance imaging (MRI) and computed tomography (CT) scanning. These imaging modalities play a crucial role in the diagnosis, staging, and monitoring of various cancers, thereby enhancing clinical outcomes.

In the context of lung cancer, low-dose chest CT screening has been increasingly adopted for early detection. This approach is particularly beneficial as it allows for the identification of lung tumors at an earlier stage, potentially leading to improved survival rates. The integration of artificial intelligence in radiomics and radiogenomics is emerging as a vital area that enhances diagnostic accuracy and personalizes risk stratification for patients. Additionally, ultrasound- and CT-guided interventions are now recognized as minimally invasive methods for diagnosing and treating pulmonary malignancies, further demonstrating the evolving landscape of imaging in oncology [6].

Moreover, CT has been established as the primary diagnostic tool in oncologic imaging, extensively used for tumor detection, staging, and follow-up. Recent developments in CT technology include the introduction of dual-layer detector technology, which enables the acquisition of spectral data without the need for additional x-ray tube or acquisitions. This advancement allows for improved image quality while simultaneously addressing the critical concern of radiation exposure, as CT accounts for a significant percentage of overall patient radiation [7].

In the realm of MRI, it has become a mainstay of non-invasive diagnostic radiology since the 1980s, primarily due to its lack of radiation exposure. Innovations such as diffusion-weighted imaging, MR elastography, and T1 mapping are currently being utilized to enhance the characterization of tumors and assess treatment responses. These advanced MRI techniques provide a more precise evaluation of tumor features, thereby facilitating individualized treatment approaches based on specific imaging biomarkers [8].

Furthermore, the advancements in imaging technologies are complemented by the development of novel imaging protocols aimed at optimizing CT procedures. This includes efforts to reduce radiation doses while maintaining satisfactory image quality, thereby improving patient safety and comfort during diagnostic imaging [7].

In summary, the latest technological advances in imaging techniques, particularly in MRI and CT scanning, are pivotal in the early detection of cancer. These innovations not only enhance diagnostic accuracy but also contribute to personalized treatment strategies, ultimately improving patient outcomes in oncology.

3 Liquid Biopsies and Circulating Biomarkers ​

3.1 Overview of Liquid Biopsy Technologies ​

Liquid biopsy has emerged as a transformative approach in the early detection of cancer, offering a minimally invasive alternative to traditional tissue biopsies. Recent advancements in liquid biopsy technologies have significantly enhanced the ability to analyze circulating biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating tumor RNAs (ctRNA), and extracellular vesicles (EVs). These biomarkers play a crucial role in early cancer diagnosis, treatment selection, monitoring, and disease assessment.

One of the major benefits of liquid biopsy is its noninvasive nature, allowing for repeated sampling from easily accessible bodily fluids such as blood, urine, and saliva. This approach facilitates real-time monitoring of disease progression and therapeutic responses, which is essential for personalized medicine. For instance, liquid biopsy has shown great potential in various cancer types, including lung, colorectal, breast, and prostate cancers, where early detection can significantly improve patient outcomes [9].

Recent innovations in nanotechnology and microfabrication have led to the development of highly precise chip-based platforms that can detect multiple biomarkers simultaneously. These platforms can overcome the limitations of detecting individual biomarkers by integrating combined target separation techniques, thus enhancing the overall sensitivity and specificity of cancer detection [10].

In addition to technological advancements, the field has also witnessed significant progress in the understanding of circulating biomarkers. For example, ctDNA analysis using next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR) has expanded the utility of liquid biopsies, enabling the detection of somatic variants and actionable genomic alterations in tumors [9]. Furthermore, the use of circulating microRNAs (miRNAs) as biomarkers has gained traction due to their stability in biological fluids and high sensitivity, which can improve diagnostic and prognostic capabilities [11].

Despite these advancements, several challenges remain in the standardization of liquid biopsy techniques, interpretation of results, and integration into clinical practice. The need for standardized protocols for sample collection, processing, and analysis is critical to ensure reproducibility and reliability of results [12]. Additionally, ongoing research is focused on overcoming technical and clinical challenges associated with biomarker development, which are being addressed by collaborative efforts such as the Liquid Biopsy Consortium [13].

Overall, liquid biopsy technologies represent a significant step forward in cancer early detection, with ongoing research and technological innovations poised to further enhance their clinical applicability and effectiveness in personalized medicine. The continuous evolution of biosensing technologies, including optical and electrochemical sensors, also contributes to achieving low detection limits and increased specificity, which are vital for the successful implementation of liquid biopsies in routine clinical settings [14].

3.2 Clinical Applications and Case Studies ​

Recent advances in cancer early detection have prominently featured liquid biopsies and circulating biomarkers, which represent a shift towards less invasive diagnostic techniques. Liquid biopsy involves the analysis of circulating tumor components in body fluids, such as blood, providing a noninvasive method for cancer diagnosis, monitoring, and treatment selection.

Liquid biopsy technologies have made significant strides in clinical applications. They facilitate the early detection of various cancer types, including lung, colorectal, breast, and prostate cancers. Notably, biomarkers such as circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) have emerged as critical components in the early diagnosis and monitoring of cancer progression and treatment responses[9][15][16].

The application of advanced genomic and molecular technologies, such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR), has enhanced the utility of liquid biopsies. These technologies allow for the detection of somatic variants and actionable genomic alterations in tumors, thereby improving the precision of cancer management[9]. Moreover, liquid biopsies have demonstrated potential in predicting treatment responses and monitoring minimal residual disease (MRD), thus aiding in the assessment of tumor heterogeneity[9].

One of the most significant advantages of liquid biopsies is their noninvasive nature, which facilitates repeated sampling and monitoring over time. This aspect is particularly valuable in assessing disease progression and therapeutic efficacy, as it allows clinicians to track changes in biomarkers without the need for invasive tissue biopsies[16][17]. For instance, studies have shown that the levels of ctDNA and CTCs can correlate with treatment responses and disease status, providing real-time insights into the patient's condition[18].

Furthermore, liquid biopsies are being integrated into precision medicine frameworks, which aim to tailor treatment strategies based on individual tumor characteristics. This integration has been shown to enhance patient outcomes by enabling more personalized treatment approaches[9][15].

Despite the promising advancements, challenges remain in standardizing liquid biopsy techniques, interpreting results, and integrating these approaches into routine clinical practice. The need for robust protocols for sample collection, processing, and analysis is critical to ensuring the reliability and reproducibility of results[9][16]. Additionally, ongoing research is focused on expanding the repertoire of detectable biomarkers and improving the sensitivity and specificity of liquid biopsy tests[16][17].

In summary, the landscape of cancer early detection is evolving with the advent of liquid biopsies and circulating biomarkers. These advancements offer significant clinical implications, presenting a dynamic, noninvasive approach to understanding tumor biology and guiding personalized treatment strategies, albeit with ongoing challenges that necessitate further investigation and refinement.

4 Genomic and Proteomic Approaches to Biomarker Discovery ​

4.1 Next-Generation Sequencing in Cancer Detection ​

Recent advances in cancer early detection have been significantly influenced by genomic and proteomic approaches, particularly through the application of next-generation sequencing (NGS) technologies. These developments have facilitated the identification of genetic, genomic, and epigenomic alterations that are crucial for understanding cancer biology and improving diagnostic capabilities.

Next-generation sequencing technologies have revolutionized cancer genome studies by enhancing the efficiency and resolution of detecting various alterations, including single nucleotide mutations, small insertions and deletions, chromosomal rearrangements, copy number variations, and DNA methylation. Comprehensive analyses utilizing whole genome, exome, and transcriptome sequencing have provided unprecedented insights into the landscape of genomic alterations in human sporadic cancers, thereby advancing the understanding of cancer biology, diagnosis, and therapy (Dong and Wang, 2012) [19].

The integration of genomic profiling into clinical practice has also been accelerated by NGS. This approach has focused initially on target identification in patients with advanced cancer, but it has expanded to include prognostication, resistance detection, disease monitoring, and early detection efforts (Borad and LoRusso, 2017) [20]. Furthermore, the advent of large-scale and high-throughput cytogenomics technologies has improved the detection and identification of tumor molecular signatures, aiding in the understanding of cancer initiation and progression. This technological progress has underscored the importance of identifying driver genes to guide targeted therapy development and predict drug resistance (Ribeiro et al., 2019) [21].

In addition to genomic approaches, proteomic technologies are emerging as powerful tools for cancer biomarker discovery. These technologies facilitate the comprehensive analysis of proteomes, enabling researchers to identify specific biomarkers that can lead to early detection and better treatment outcomes. Proteomic analysis has demonstrated the potential to accelerate the discovery of disease-related biomarkers, which is critical since early detection significantly impacts cancer prognosis (Petricoin and Liotta, 2002) [22].

The combination of genomic and proteomic technologies offers unique opportunities for the early detection of cancer. The integration of these approaches allows for a more comprehensive understanding of tumor biology, which is essential for developing effective screening tests and improving patient outcomes. As these technologies continue to evolve, they hold the promise of transforming the landscape of cancer interception and management in the near future (Beane et al., 2017) [23].

In summary, the latest advances in cancer early detection through genomic and proteomic approaches, particularly utilizing next-generation sequencing, have opened new avenues for identifying biomarkers that can lead to timely diagnosis and improved therapeutic strategies. These advancements are pivotal in addressing the critical need for early detection and intervention in cancer care.

4.2 Proteomic Profiling and Its Implications ​

Recent advances in cancer early detection have been significantly influenced by genomic and proteomic approaches aimed at biomarker discovery. Cancer remains a leading cause of mortality globally, with late diagnosis being a major factor in poor survival rates. Therefore, the integration of advanced technologies to enhance early detection is critical.

One of the foremost developments in this field is the application of proteogenomic strategies, which combine proteomic and genomic technologies. This integrated approach facilitates the identification of novel biomarkers for early diagnosis and prognosis. The identification of driver mutations—somatic DNA lesions that initiate tumorigenesis—coupled with the aberrant regulation of oncoproteins, underlines the necessity of a dual approach in understanding cancer progression and metastasis (Shukla et al., 2015)[24]. Recent advancements in human genome-based detection methods, including Next-Generation Sequencing (NGS), digital PCR, and circulating free DNA (cfDNA) technologies, have shown promise in identifying oncogenic mutations and other critical genomic alterations associated with various cancers.

Moreover, proteomics has emerged as a powerful tool for investigating the distribution of proteins within biological systems, leading to significant insights into cancer biology. The development of new proteomic databases that include somatic variants and post-translational modifications is crucial for improving diagnostic accuracy. Utilizing multiple proteomic and genomic biomarkers rather than relying on a single marker can enhance the predictive power for treatment outcomes and enable better monitoring of treatment responses (Beane et al., 2017)[23].

Technological advancements such as mass spectrometry and multiplexed immunoassays have improved the sensitivity and specificity of protein biomarker detection in plasma. These innovations allow for the identification of low-abundance tumor-associated proteins that may indicate early-stage cancers. For instance, nanomechanical devices have been proposed to detect proteins at extremely low concentrations, potentially identifying biomarkers before tumors metastasize (Kosaka et al., 2018)[25].

Additionally, ongoing research emphasizes the importance of early detection through proteomic analysis, which can reveal distinct changes in the proteome associated with the transition from healthy to neoplastic states. The use of advanced techniques, such as two-dimensional electrophoresis and mass spectrometry, alongside bioinformatics tools, has facilitated the identification and validation of potential biomarkers for early cancer detection (Srinivas et al., 2001)[26].

In summary, the latest advances in cancer early detection are characterized by a synergistic approach combining genomic and proteomic technologies. This dual strategy enhances the discovery of biomarkers that can significantly improve early diagnosis, ultimately leading to better clinical outcomes and personalized treatment strategies.

5 Multi-Omics Strategies for Comprehensive Cancer Detection ​

5.1 Integration of Genomic, Transcriptomic, and Proteomic Data ​

Recent advances in cancer early detection have prominently featured the integration of multi-omics strategies, which encompass genomic, transcriptomic, proteomic, metabolomic, and epigenomic data. These approaches provide a comprehensive understanding of the molecular heterogeneity of various cancers, significantly enhancing the specificity and sensitivity of early cancer diagnostics.

One of the critical developments in this field is the application of multi-omics technologies to improve early detection methods. By integrating diverse biological data, researchers can uncover complex biological mechanisms that underlie cancer initiation and progression. For instance, multi-omics analyses have facilitated the identification of novel biomarkers, genetic mutations, and molecular signatures associated with different cancer types, thereby offering promising avenues for early diagnosis and risk stratification (Hachem et al. 2024; Milner & Lennerz 2024).

In particular, the integration of genomic data reveals genetic alterations that drive tumorigenesis, while transcriptomic analyses help in understanding the expression profiles of cancer-related genes. Proteomics contributes valuable insights into protein interactions and signaling pathways that may be altered in cancer. Metabolomics, which analyzes metabolic changes in cells, has also emerged as a promising tool for identifying early-stage tumors through the detection of specific metabolites that are indicative of malignancy (Liu et al. 2025; Yan et al. 2025).

Moreover, the implementation of artificial intelligence (AI) and machine learning algorithms to analyze multi-omics data has further enhanced the ability to predict cancer outcomes and treatment responses. These technologies allow for the integration of large datasets, leading to the development of predictive models that can identify patients at high risk for developing cancer and tailor early intervention strategies accordingly (Camps et al. 2025).

The potential of multi-omics approaches extends beyond mere detection; they also support the development of personalized treatment strategies. By understanding the unique molecular profiles of tumors, clinicians can design targeted therapies that are more effective and less toxic to patients (Zhou et al. 2024). Furthermore, the continuous evolution of high-throughput sequencing technologies and computational tools has made it feasible to analyze multi-omics data at a scale that was previously unattainable, paving the way for more comprehensive cancer screening programs (Menyhárt & Győrffy 2021).

In summary, the latest advances in cancer early detection are significantly driven by multi-omics strategies that integrate various biological data types. These innovations not only enhance the ability to detect cancer at earlier stages but also contribute to the personalization of treatment, ultimately improving patient outcomes and transforming cancer care. The ongoing research and clinical applications of these technologies are expected to revolutionize the landscape of cancer diagnostics and management (Milner & Lennerz 2024; Liu et al. 2025).

5.2 Challenges and Future Directions ​

Recent advances in cancer early detection have increasingly centered on multi-omics strategies, which integrate various biological data types to enhance diagnostic accuracy and patient outcomes. Multi-omics approaches involve the combination of genomics, transcriptomics, proteomics, metabolomics, and other omic data to provide a comprehensive understanding of tumor biology and the molecular mechanisms underlying cancer development.

The innovation of liquid biopsy has emerged as a promising avenue for early cancer detection, offering the potential to revolutionize cancer management through the analysis of tumor-derived components from body fluids. Integrative analysis of different tumor-derived omics data can outperform single modality data, allowing for better cancer detection and monitoring. This is particularly important for identifying molecular residual disease and assessing treatment responses, which are critical for improving patient outcomes (Chen et al., 2023) [27].

Advancements in artificial intelligence (AI) and machine learning have further fueled the development of cancer precision medicine. AI algorithms are capable of analyzing complex multi-modal data streams, thereby enhancing the integration of multi-omics data for improved early cancer screening, diagnosis, and prognosis prediction. These AI-driven multi-omics analyses have shown promise in identifying biomarkers that are crucial for early detection and personalized treatment strategies (He et al., 2023) [28].

In addition to AI, recent studies have highlighted the importance of characterizing premalignant lesions (PMLs) across various cancer types. Understanding the molecular and cellular evolution from precancerous states to invasive malignancies offers significant opportunities for early detection and interception of cancer. Multi-omics technologies provide insights into PML-induced tumorigenesis, emphasizing the need for high-precision early-diagnosis biomarkers and targeted preventive strategies (Zhang et al., 2025) [29].

However, several challenges remain in the implementation of multi-omics strategies for early cancer detection. Data heterogeneity, insufficient algorithm generalization, and high costs are significant barriers that limit clinical translation. Furthermore, the complexity of integrating diverse omic data requires the development of robust computational methods and standardization protocols to ensure reliable results across different platforms and studies (Liu et al., 2025) [30].

Looking ahead, the integration of single-cell multi-omics and advanced AI technologies holds promise for enhancing the precision of cancer diagnostics and treatment. Continued research and innovation in multi-omics approaches are essential for overcoming current limitations and fully realizing the potential of these strategies in clinical settings. The transformative potential of multi-omics in early cancer detection underscores the importance of interdisciplinary collaboration among researchers, clinicians, and data scientists to improve patient outcomes and advance the field of precision oncology (Milner & Lennerz, 2024) [31].

6 Challenges in Clinical Implementation ​

6.1 Regulatory and Ethical Considerations ​

Recent advancements in cancer early detection have been significant, particularly in the development of biomarkers and innovative technologies. Emerging biomarkers, such as circulating tumor DNA (ctDNA), exosomes, and microRNAs (miRNAs), have shown promising potential for non-invasive and efficient cancer identification in early stages. The review by Zafar et al. (2025) emphasizes that the use of liquid biopsies and nanobiosensors, alongside artificial intelligence and next-generation sequencing (NGS), is transforming the landscape of biomarker discovery and application[32].

Despite these advancements, there are considerable challenges in clinical implementation. For instance, while liquid biopsy-based multi-cancer early detection (MCED) tests have reached clinical trial phases, none have been approved for clinical use, raising uncertainties regarding their efficacy and applicability[33]. Key challenges include achieving optimal sensitivity for early-stage cancers, minimizing false positives and negatives, and ensuring equitable access to these tests[33]. Additionally, the complexity of exosome isolation and inter-patient variability in miRNA expression further complicate the clinical utility of these biomarkers[32].

Regulatory considerations are paramount as the field of early cancer detection evolves. The integration of new technologies into clinical practice necessitates rigorous validation to demonstrate clinical utility before they can be widely adopted. Regulatory bodies face the challenge of establishing standards for the approval of these innovative tests, which may require new frameworks to accommodate the unique characteristics of biomarkers derived from liquid biopsies and other novel methodologies[34].

Ethical considerations also play a crucial role in the implementation of early detection strategies. The risk of overdiagnosis and overtreatment, particularly in cases where cancers may not progress, poses ethical dilemmas for healthcare providers and patients alike[35]. There is a need for transparent communication regarding the potential benefits and limitations of early detection technologies, ensuring that patients can make informed decisions about their care[36].

In conclusion, while advancements in cancer early detection are promising, significant challenges remain in their clinical implementation, regulatory approval, and ethical considerations. Future research must focus on overcoming these hurdles through multidisciplinary collaboration and the establishment of standardized protocols to enhance the clinical utility of early detection methods[32][33].

6.2 Accessibility and Cost-Effectiveness ​

Recent advances in cancer early detection have been significantly shaped by the development of innovative technologies and methodologies, although challenges in clinical implementation, particularly regarding accessibility and cost-effectiveness, remain critical concerns.

Emerging biomarkers, including circulating tumor DNA (ctDNA), exosomes, and microRNAs (miRNAs), have shown promising potential for non-invasive early cancer detection. These biomarkers are integral to the evolution of liquid biopsies, which enable the identification of cancer in its early stages without the need for invasive procedures [32]. Moreover, advancements in artificial intelligence (AI) and next-generation sequencing (NGS) are transforming biomarker discovery, providing efficient and reliable methods for early diagnosis [32]. AI is particularly noteworthy for its role in enhancing diagnostic accuracy and interpretation of complex data from various biomarkers [4].

Liquid biopsies have gained traction as a minimally invasive approach to detect tumors at the molecular level, monitor cancer progression, and predict treatment responses. This method capitalizes on analyzing biomarkers present in bodily fluids, which facilitates early detection [4]. However, challenges such as low biomarker concentration, fragmentation of ctDNA, and variability in miRNA expression pose significant hurdles to widespread clinical application [32].

Microneedle-based liquid biopsy technologies represent another innovative advance, particularly suited for low-resource settings. This method allows for the capture of interstitial fluid directly from the skin, presenting a practical alternative for cancer diagnosis where traditional methods may be cost-prohibitive or logistically challenging [37]. Such approaches are critical for enhancing accessibility to cancer diagnostics in underserved populations.

The integration of AI with smartphone-based imaging systems is another notable development. These portable, cost-effective tools can provide early cancer detection in resource-limited settings. However, they face challenges related to imaging quality and computational limitations [1]. Addressing these challenges through improved AI algorithms can enhance the reliability and accuracy of these diagnostic tools, making them more suitable for clinical use [1].

Despite these advancements, significant barriers to implementation persist. High costs associated with advanced diagnostic technologies, along with the complexity of results interpretation, limit their adoption in clinical practice [4]. Moreover, the lack of standardized protocols for biomarker assays and the inter-patient variability further complicate the clinical landscape [4].

Equity in access to cancer detection technologies is another pressing issue. Many innovations are not readily accessible in low-resource settings, which exacerbates disparities in cancer outcomes [32]. Future research must focus on overcoming these barriers, promoting multidisciplinary collaboration, and developing standardized protocols to enhance the clinical utility of these diagnostic approaches [32].

In conclusion, while significant strides have been made in cancer early detection through innovative technologies and biomarkers, the challenges of clinical implementation, particularly concerning accessibility and cost-effectiveness, necessitate continued efforts to ensure that these advancements benefit all populations equitably.

7 Conclusion ​

The latest advances in cancer early detection have revealed significant findings across various technological domains, emphasizing the importance of early diagnosis in improving patient outcomes. The integration of artificial intelligence in imaging techniques, particularly in MRI and CT scans, has enhanced diagnostic accuracy, allowing for earlier detection of malignancies. Liquid biopsies have emerged as a non-invasive alternative, enabling real-time monitoring of circulating biomarkers, thus facilitating personalized medicine approaches. Furthermore, genomic and proteomic strategies have provided insights into the molecular underpinnings of cancer, paving the way for the discovery of novel biomarkers. The multi-omics approach, which integrates genomic, transcriptomic, and proteomic data, represents a paradigm shift in cancer diagnostics, offering comprehensive insights into tumor biology. However, the path to clinical implementation is fraught with challenges, including regulatory hurdles, ethical considerations, and issues of accessibility and cost-effectiveness. Future research should focus on addressing these challenges through collaborative efforts and the development of standardized protocols, ensuring that the benefits of these innovations reach diverse populations. Overall, the evolving landscape of cancer early detection holds promise for significantly improving cancer management and patient outcomes in the future.

References ​

  • [1] Bofan Song;Rongguang Liang. Integrating artificial intelligence with smartphone-based imaging for cancer detection in vivo.. Biosensors & bioelectronics(IF=10.5). 2025. PMID:39616900. DOI: 10.1016/j.bios.2024.116982.
  • [2] Ruth Etzioni;Nicole Urban;Scott Ramsey;Martin McIntosh;Stephen Schwartz;Brian Reid;Jerald Radich;Garnet Anderson;Leland Hartwell. The case for early detection.. Nature reviews. Cancer(IF=66.8). 2003. PMID:12671663. DOI: 10.1038/nrc1041.
  • [3] Mahima Mishra;Rubai Ahmed;Deepak Kumar Das;Devlina Das Pramanik;Sandeep Kumar Dash;Arindam Pramanik. Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers.. ACS biomaterials science & engineering(IF=5.5). 2024. PMID:38950521. DOI: 10.1021/acsbiomaterials.4c00606.
  • [4] Anca-Narcisa Neagu;Pathea S Bruno;Claudiu-Laurentiu Josan;Natalie Waterman;Hailey Morrissiey;Victor T Njoku;Costel C Darie. In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.. Proteomes(IF=3.6). 2025. PMID:41133620. DOI: 10.3390/proteomes13040047.
  • [5] Hedvig Hricak;Marius E Mayerhoefer;Ken Herrmann;Jason S Lewis;Martin G Pomper;Christopher P Hess;Katrine Riklund;Andrew M Scott;Ralph Weissleder. Advances and challenges in precision imaging.. The Lancet. Oncology(IF=35.9). 2025. PMID:39756454. DOI: 10.1016/S1470-2045(24)00395-4.
  • [6] Ádám Domonkos Tárnoki;Dávid László Tárnoki;Marta Dąbrowska;Magdalena Knetki-Wróblewska;Armin Frille;Harrison Stubbs;Kevin G Blyth;Amanda Dandanell Juul. New developments in the imaging of lung cancer.. Breathe (Sheffield, England)(IF=3.4). 2024. PMID:38595936. DOI: 10.1183/20734735.0176-2023.
  • [7] V Granata;R Fusco;G Bicchierai;D Cozzi;G Grazzini;G Danti;F De Muzio;N Maggialetti;O Smorchkova;M D'Elia;M C Brunese;R Grassi;G Giacobbe;F Bruno;P Palumbo;G V Lacasella;L Brunese;R Grassi;V Miele;A Barile. Diagnostic protocols in oncology: workup and treatment planning. Part 1: the optimitation of CT protocol.. European review for medical and pharmacological sciences(IF=3.3). 2021. PMID:34859859. DOI: 10.26355/eurrev_202111_27246.
  • [8] Arya Haj-Mirzaian;Ana Kadivar;Ihab R Kamel;Atif Zaheer. Updates on Imaging of Liver Tumors.. Current oncology reports(IF=5.0). 2020. PMID:32296952. DOI: 10.1007/s11912-020-00907-w.
  • [9] Ho-Yin Ho;Kei-See Kasey Chung;Chau-Ming Kan;Sze-Chuen Cesar Wong. Liquid Biopsy in the Clinical Management of Cancers.. International journal of molecular sciences(IF=4.9). 2024. PMID:39201281. DOI: 10.3390/ijms25168594.
  • [10] Kimberley Clack;Narshone Soda;Surasak Kasetsirikul;Rabbee G Mahmudunnabi;Nam-Trung Nguyen;Muhammad J A Shiddiky. Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy.. Small (Weinheim an der Bergstrasse, Germany)(IF=12.1). 2023. PMID:36631277. DOI: 10.1002/smll.202205856.
  • [11] Lorena Quirico;Francesca Orso. The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies.. Cancer drug resistance (Alhambra, Calif.)(IF=5.2). 2020. PMID:35582611. DOI: 10.20517/cdr.2019.103.
  • [12] Gabriella Cirmena;Martina Dameri;Francesco Ravera;Piero Fregatti;Alberto Ballestrero;Gabriele Zoppoli. Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications.. Cancers(IF=4.4). 2021. PMID:34298675. DOI: 10.3390/cancers13143460.
  • [13] Syeda Maheen Batool;Anudeep Yekula;Prerna Khanna;Tiffaney Hsia;Austin S Gamblin;Emil Ekanayake;Ana K Escobedo;Dong Gil You;Cesar M Castro;Hyungsoon Im;Tugba Kilic;Michelle Andrea Garlin;Johan Skog;Daniela M Dinulescu;Jonathan Dudley;Nishant Agrawal;Jordan Cheng;Fereidoun Abtin;Denise R Aberle;David Chia;David Elashoff;Tristan Grognan;Kostyantyn Krysan;Scott S Oh;Charles Strom;Michael Tu;Fang Wei;Rena R Xian;Steven J Skates;David Y Zhang;Thi Trinh;Mark Watson;Rebecca Aft;Siddarth Rawal;Ashutosh Agarwal;Susan B Kesmodel;Changhuei Yang;Cheng Shen;Fred H Hochberg;David T W Wong;Abhijit A Patel;Nickolas Papadopoulos;Chetan Bettegowda;Richard J Cote;Sudhir Srivastava;Hakho Lee;Bob S Carter;Leonora Balaj. The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring.. Cell reports. Medicine(IF=10.6). 2023. PMID:37716353. DOI: 10.1016/j.xcrm.2023.101198.
  • [14] Panagiota M Kalligosfyri;Eleni Lamprou;Despina P Kalogianni. Emerging Sensing Technologies for Liquid Biopsy Applications: Steps Closer to Personalized Medicine.. Sensors (Basel, Switzerland)(IF=3.5). 2024. PMID:39771639. DOI: 10.3390/s24247902.
  • [15] Qi Zhang;Xiaoli Zhang;Peipei Xie;Wen Zhang. Liquid biopsy: An arsenal for tumour screening and early diagnosis.. Cancer treatment reviews(IF=10.5). 2024. PMID:38851148. DOI: 10.1016/j.ctrv.2024.102774.
  • [16] Zhenhui Chen;Chenghao Li;Yue Zhou;Yinghao Yao;Jiaqi Liu;Min Wu;Jianzhong Su. Liquid biopsies for cancer: From bench to clinic.. MedComm(IF=10.7). 2023. PMID:37492785. DOI: 10.1002/mco2.329.
  • [17] Wenxiang Wang;Yue He;Fan Yang;Kezhong Chen. Current and emerging applications of liquid biopsy in pan-cancer.. Translational oncology(IF=4.1). 2023. PMID:37315508. DOI: 10.1016/j.tranon.2023.101720.
  • [18] Sridevi Addanki;Salyna Meas;Vanessa Nicole Sarli;Balraj Singh;Anthony Lucci. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.. International journal of molecular sciences(IF=4.9). 2022. PMID:35887191. DOI: 10.3390/ijms23147843.
  • [19] Hui Dong;Shengyue Wang. Exploring the cancer genome in the era of next-generation sequencing.. Frontiers of medicine(IF=3.5). 2012. PMID:22460448. DOI: 10.1007/s11684-012-0182-x.
  • [20] Mitesh J Borad;Patricia M LoRusso. Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer.. Mayo Clinic proceedings(IF=6.7). 2017. PMID:28982488. DOI: 10.1016/j.mayocp.2017.08.002.
  • [21] Ilda Patrícia Ribeiro;Joana Barbosa Melo;Isabel Marques Carreira. Cytogenetics and Cytogenomics Evaluation in Cancer.. International journal of molecular sciences(IF=4.9). 2019. PMID:31547595. DOI: 10.3390/ijms20194711.
  • [22] Emanuel F Petricoin;Lance A Liotta. Proteomic analysis at the bedside: early detection of cancer.. Trends in biotechnology(IF=14.9). 2002. PMID:12570157. DOI: 10.1016/s1471-1931(02)00204-5.
  • [23] Jennifer Beane;Joshua D Campbell;Julian Lel;Jessica Vick;Avrum Spira. Genomic approaches to accelerate cancer interception.. The Lancet. Oncology(IF=35.9). 2017. PMID:28759388. DOI: 10.1016/S1470-2045(17)30373-X.
  • [24] Hem D Shukla;Javed Mahmood;Zeljko Vujaskovic. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.. Cancer letters(IF=10.1). 2015. PMID:26276717. DOI: .
  • [25] Priscila M Kosaka;Montserrat Calleja;Javier Tamayo. Optomechanical devices for deep plasma cancer proteomics.. Seminars in cancer biology(IF=15.7). 2018. PMID:28867489. DOI: 10.1016/j.semcancer.2017.08.011.
  • [26] P R Srinivas;S Srivastava;S Hanash;G L Wright. Proteomics in early detection of cancer.. Clinical chemistry(IF=6.3). 2001. PMID:11568117. DOI: .
  • [27] Geng Chen;Jing Zhang;Qiaoting Fu;Valerie Taly;Fei Tan. Integrative analysis of multi-omics data for liquid biopsy.. British journal of cancer(IF=6.8). 2023. PMID:36357703. DOI: 10.1038/s41416-022-02048-2.
  • [28] Xiujing He;Xiaowei Liu;Fengli Zuo;Hubing Shi;Jing Jing. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine.. Seminars in cancer biology(IF=15.7). 2023. PMID:36596352. DOI: 10.1016/j.semcancer.2022.12.009.
  • [29] Feiran Zhang;Ziyi Zhou;Peng Zhang;Shao Li. Multi-Omics Meets Premalignancy: Paving the Way for Early Prevention of Cancer.. Research (Washington, D.C.)(IF=10.7). 2025. PMID:41255572. DOI: 10.34133/research.0930.
  • [30] Yuqing Liu;Feng Gao;Yang Cheng;Liang Qi;Haining Yu. Applications and advances of multi-omics technologies in gastrointestinal tumors.. Frontiers in medicine(IF=3.0). 2025. PMID:40771479. DOI: 10.3389/fmed.2025.1630788.
  • [31] Danny A Milner;Jochen K Lennerz. Technology and Future of Multi-Cancer Early Detection.. Life (Basel, Switzerland)(IF=3.4). 2024. PMID:39063587. DOI: 10.3390/life14070833.
  • [32] Sameen Zafar;Amna Hafeez;Hania Shah;Iqra Mutiullah;Arslan Ali;Khushbukhat Khan;Gabriela Figueroa-González;Octavio Daniel Reyes-Hernández;Laura Itzel Quintas-Granados;Sheila I Peña-Corona;Lashyn N Kiyekbayeva;Monica Butnariu;Cristina-Elena Tota;Angela Caunii;Dietrich Büsselberg;Javad Sharifi-Rad;Gerardo Leyva-Gómez. Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.. European journal of medical research(IF=3.4). 2025. PMID:40826140. DOI: 10.1186/s40001-025-03003-6.
  • [33] Yongjie Xu;Sibo Zhu;Changfa Xia;Hui Yu;Si Shi;Kezhong Chen;Yue He;Chuxia Deng;Haoxuan Jin;Jing Liu;Rebecca Fitzgerald;Partha Basu;Wanqing Chen. Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.. Science bulletin(IF=21.1). 2025. PMID:40670203. DOI: 10.1016/j.scib.2025.06.030.
  • [34] Jamie E Medina;Nicholas C Dracopoli;Peter B Bach;Anna Lau;Robert B Scharpf;Gerrit A Meijer;Claus Lindbjerg Andersen;Victor E Velculescu. Cell-free DNA approaches for cancer early detection and interception.. Journal for immunotherapy of cancer(IF=10.6). 2023. PMID:37696619. DOI: 10.1136/jitc-2022-006013.
  • [35] Yiwey Shieh;Martin Eklund;George F Sawaya;William C Black;Barnett S Kramer;Laura J Esserman. Population-based screening for cancer: hope and hype.. Nature reviews. Clinical oncology(IF=82.2). 2016. PMID:27071351. DOI: 10.1038/nrclinonc.2016.50.
  • [36] Anna Dowrick;Sue Ziebland;Tanvi Rai;Claire Friedemann Smith;Brian D Nicholson. A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care.. The Lancet. Oncology(IF=35.9). 2024. PMID:38848741. DOI: 10.1016/S1470-2045(24)00102-5.
  • [37] Chaima Merzougui;Xi Yang;Dianhuai Meng;Yan Huang;Xiangwei Zhao. Microneedle Array-Based Dermal Interstitial Fluid Biopsy for Cancer Diagnosis: Advances and Challenges.. Advanced healthcare materials(IF=9.6). 2025. PMID:39887596. DOI: 10.1002/adhm.202404420.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Cancer Early Detection · Artificial Intelligence · Liquid Biopsies · Biomarkers · Multi-Omics Strategies

© 2025 MaltSci